CENTRAL PROCUREMENT & SUPPLIES UNIT
MINISTRY FOR HEALTH
UB002, Industrial Estate, San Gwann - SGN3000
Tel: (+356) 2592 4000 E-mail: info.cpsu@gov.mt

**Our Ref**: CPSU 164073N20JP
**RFP Publication Ref**: 021-056/20
**Publication Date:** 08/05/20
**Closing Date:** 08/06/20 extended till 10/06/20

## Request for Participation (Negotiation) for the Supply of Natalizumab 300mg vials

# Clarification No.3 – dated 09/06/20

## Questions submitted by Economic Operators

**Question 1:** With reference to clarification answer number no 1 - the RFP as issued directly excludes competition and fails to provide a fair an equal level playing field for bidders to participate in this request.

The reference to the issue of a more comprehensive contract (past dated 2017) further accentuates the exclusion of alternative treatments, which are equally available In the market for the same indications and also provide wider coverage of treatments thus by having encompassing and additional approved indications beyond those of Natalizumab. The delay in the process of this more comprehensive contract, has in turned created a unfair advantage in favour of a single bidder, in which the comprehensive contract has been limited to Natalizumab excluding other products from being used or considered and in the interim ongoing requests for Natalizumab only keep being issued.

In effect the process has ensured the elimination of a fair and equal process and denies competition, thus by offering protection and grants an unfair and sole advantage in favour of a single brand and bidder.

There are alternative treatments for patients within the indications requested which may be offered under this RFP and therefore also ensures continuation of treatment.

As prospective bidders with an alternative and approved and more advantageous product, we request such alternative products are accepted for this RFP, and that the more comprehensive contract is in fact cancelled and re issued in view of its excessive period for adjudication, which has in effect created a monopolistic position in favour of one brand and further postponed the timing for approved alternatives to be offered.

**Answer 1:** Kindly note that as per DPA, equivalents will be considered if supporting evidence is submitted in order to verify that the product is interchangeable with Natalizumab 300mg concentrate for solution for infusion and that it is as effective and safe for use in stable patients on Natalizumab.

**The above clarifications are constituted to form an integral part of the original published procurement documentation.**